Supernus製藥 SUPN 深 滬
等待開盤 10-06 09:30:00 美东时间
48.35
+0.390
+0.81%
華盛通- 最 高49.66
- 今 開47.97
- 成交量 93.94万股
- 最 低 47.97
- 昨 收 47.96
- 總市值 27.07亿
- 52周最高 49.66
- 市盈率 靜 36.63
- 換手率 1.68%
- 52周最低 29.16
- 委 比 -78.61%
- 總股本 5598.96万
- 歷史最高 61.25
- 量 比 1.64
- 振 幅 3.52%
- 歷史最低 4.30
- 每 手 1
- 風險率 4.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $63
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $46 to $63.
09-30 22:13
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
09-30 00:06
Piper Sandler Maintains Neutral on Supernus Pharmaceuticals, Raises Price Target to $40
Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and raises the price target from $36 to $40.
08-29 21:18
Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals, Inc. announced that its management will participate in three September investor conferences: the Cantor Global Healthcare Conference on September 3, 2025, in New York; the Wells Fargo Healthcare Conference on September 4, 2025, in Boston; and TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit virtually on September 18, 2025. Investors can arrange meetings by contacting the conference coordinators...
08-27 20:15
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $46.
08-06 22:14
Supernus Pharmaceuticals Raises FY2025 Sales Guidance from $600.000M-$630.000M to $670.000M-$700.000M vs $632.103M Est
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2025 sales outlook from $600.000 million-$630.000 million to $670.000 million-$700.000 million vs $632.103 million estimate.
08-06 04:27
Supernus Pharmaceuticals Q2 EPS $0.40 Beats $0.11 Estimate, Sales $180.916M Beat $154.061M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.11 by 273.83 percent. This is a 11.11 percent increase over earnings of $0.36 per
08-06 04:09
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its neuropsychiatric portfolio with ZURZUVAE® (zuranolone), the first FDA-approved oral treatment for postpartum depression. The deal diversifies Supernus' revenue base, adds a CNS discovery platform, and is projected to generate up to $200 million in annual cost synergies, becoming accretive in 2026. The acquisition also includes contingent value rights for Sage s...
07-31 12:44
